-
Basel, December 18, 2020 — The U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for inclisiran, a potential treatment for hyperlipidemia in adults who have elevated low-density lipoprotein cholesterol (LDL-C) while being on a maximum tolerated dose of a statin therapy. The…Reimagine MedicineLiving With Disease
-
The digital press release with multimedia content can be accessed here:Reimagine MedicineNeuroscienceMedical InnovationsLiving With Disease
-
Basel, February 16, 2021 — Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure1. Benefits are most clearly evident in…Reimagine MedicineNeuroscienceMedical InnovationsLiving With Disease
-
Basel, February 26, 2021 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted the final opinion for a type II label variation for Cosentyx® (secukinumab) to include data for axial manifestations of psoriatic arthritis (PsA), from the first-of-its-kind MAXIMISE…Reimagine MedicineLiving With Disease
-
One patient’s story reveals the hidden obstacles to better health – and opportunities to help clear them.
Access to HealthcareDisease AwarenessGenetic DiseaseLiving With DiseasePatient Voices -
It’s time to change the conversation. Patient inspired and community led, Sound Up aims to empower people affected by lung cancer in raising the volume to vocally self-advocate.CancerLiving With DiseaseOncologyPatient VoicesSocial Commitment
-
AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1Reimagine MedicineNovartis Gene TherapiesLiving With Disease
-
REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular AtrophyReimagine MedicineNovartis Gene TherapiesLiving With Disease
-
AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular AtrophyReimagine MedicineNovartis Gene TherapiesLiving With Disease
-
AveXis Announces Proposed Public Offering of Common StockReimagine MedicineNovartis Gene TherapiesLiving With Disease
-
AveXis Announces Pricing of Public Offering of Common StockReimagine MedicineNovartis Gene TherapiesLiving With Disease
-
AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesReimagine MedicineNovartis Gene TherapiesLiving With Disease
-
One patient’s story reveals the hidden obstacles to better health – and opportunities to help clear them.